1 month Zacks Research Analysts Raise Earnings Estimates for SRPTMarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Research analysts at Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a report released on Monday, October 21st. Zacks Research ana…
Earnings · Nasdaq 100 · Science
X